Ning Huang

Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer

A. Khorana, T. Bond, J. Barron, 2023, Journal for ImmunoTherapy of Cancer.

Abstract CT022: CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden

P. Ascierto, M. Burotto, T. Ciuleanu, 2022, Cancer Research.

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden

T. Ciuleanu, J. Vuky, G. Kollia, 2024, Journal for immunotherapy of cancer.